Stay updated on Niraparib vs Physician's Choice in BRCA+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Niraparib vs Physician's Choice in BRCA+ Breast Cancer Clinical Trial page.

Latest updates to the Niraparib vs Physician's Choice in BRCA+ Breast Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe displayed ClinicalTrials.gov site revision changed from v3.8.0 to v3.8.1, while the study information remained unchanged.SummaryDifference0.0%

- Check8 days agoChange DetectedThe clinical trial record for the niraparib-versus-physician’s-choice breast cancer study is displayed, with study design, results, eligibility, and participating locations. It states that the study was terminated due to futility and is no longer recruiting.SummaryDifference100%

- Check15 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0, while the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check29 days agoChange DetectedA site-wide NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the page, and the site revision changes to v3.7.2. The study record itself still displays a 403 error.SummaryDifference1%

- Check43 days agoChange DetectedThe ClinicalTrials.gov study page still displays a 403 Forbidden error. Its footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check57 days agoChange DetectedAccess to the study record NCT01905592 is blocked by a 403 Forbidden error, removing the study details and locations from the page. Users are presented with a 403 error page instead of the expected study information.SummaryDifference18%

Stay in the know with updates to Niraparib vs Physician's Choice in BRCA+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Niraparib vs Physician's Choice in BRCA+ Breast Cancer Clinical Trial page.